| Literature DB >> 27977760 |
Patrick Saunders-Hastings1, Jane Reisman1, Daniel Krewski1.
Abstract
BACKGROUND: Influenza pandemics occur when a novel influenza strain, to which humans are immunologically naïve, emerges to cause infection and illness on a global scale. Differences in the viral properties of pandemic strains, relative to seasonal ones, can alter the effectiveness of interventions typically implemented to control seasonal influenza burden. As a result, annual control activities may not be sufficient to contain an influenza pandemic.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27977760 PMCID: PMC5158032 DOI: 10.1371/journal.pone.0168262
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Systematic review search strategy as executed in Medline.
| 1 | Influenza, human/ |
| 2 | Exp Influenzavirus A/ |
| 3 | 1 or 2 |
| 4 | Pandemics/ |
| 5 | (pandemic* adj3 (influenza* or flu* or grippe)).tw. |
| 6 | 4 or 5 |
| 7 | 3 and 6 |
| 8 | Systematic review.tw. |
| 9 | Meta-analysis.tw. |
| 10 | Meta analysis.tw. |
| 11 | Or/8-10 |
| 12 | 7 and 11 |
Exclusion criteria for systematic reviews and meta-analyses of pandemic influenza interventions.
| Criterion | Rationale |
|---|---|
| Does not deal with human populations | Animal models may not give accurate representation of impact in humans |
| Does not include studies on pandemic influenza, but deals exclusively with seasonal influenza or other condition | Experience of pandemic influenza may not reflect that of seasonal influenza |
| Exclusively reviews in vivo and/or in vitro studies, or mathematical modeling studies | Purpose of study is to examine the behaviour of influenza within human populations, rather than genetic considerations |
| Does not review an intervention to contain pandemic influenza infection | Purpose of this review is to quantify intervention effectiveness |
| Does not use infection/transmission risk/rate as an outcome measure | Purpose of this review is to quantify intervention potential to contain pandemic transmission |
| Only the abstract is available | Must be able to assess article in its entirety |
| Not a peer-reviewed systematic review or meta-analysis article | Seeking to compare over-arching intervention patterns across heterogeneous settings |
Fig 1Systematic review flow diagram.
Summary of reviews included in the systematic review of pandemic influenza interventions.
| Systematic Review | Population | Total Studies (N) | Pandemic Studies for Meta-analysis | Pandemic Meta-analysis Population Size (N) | Intervention | Outcome | AMSTAR Quality (low, moderate, high) | Quality of Evidence |
|---|---|---|---|---|---|---|---|---|
| Breteler et al., 2013 | Schoolchildren in China during 2009 pandemic | 41 | 1 | 95,244 | Vaccination (two doses of PANFLU1) | Laboratory-confirmed influenza | High | Only a single study was retrieved |
| Chien et al., 2010 | Civilian and military populations during 1918 pandemic | 13 | 13 | 1,956,492 | Mixed killed bacterial vaccines | Influenza incidence | Moderate | Significant heterogeneity among studies; low scientific quality of 1918 vaccine studies; inconsistent reporting of influenza incidence |
| Demicheli et al., 2014 | Healthy adults and pregnant women during 1968 pandemic | 90 | 6 | 33,768 | 1968 and 2009 pandemic vaccines | Influenza or ILI cases | High | Methodological quality was rated as good for 10%; high risk of bias for 20%; impact of bias could not be determined for 70% |
| Fielding et al., 2014 | General population during 2009 pandemic | 11 | 11 | 1,527 | Oseltamivir | Duration of viral shedding | Moderate | Significant heterogeneity noted; prevented meta-analysis and limits scope |
| Jackson et al., 2013 | General population during 1918, 1968, and 2009 pandemics | 79 | 57 | N/A | School closure | Cumulative and peak influenza attack rates | Moderate | Significant heterogeneity noted; prevented meta-analysis and limits scope |
| Jefferson et al., 2008 | General population during 1968 pandemic | 22 | 10 | 12,575 | Amantadine prophylaxis | Influenza or ILI cases | High | Significant heterogeneity noted; little information on randomization procedures for studies reviewed |
| Jefferson et al., 2014 | Healthy children (under 16) during 2009 pandemic | 75 | 5 | Not reported | 2009 pandemic vaccine | Influenza infection | High | Generally poor methodological quality of studies included; poor reporting and high risk of bias |
| Li et al., 2016 | General population during 2009 pandemic | 30 | 12 | 1,469 | Traditional Chinese medicine | Duration of viral shedding | High | Small sample size limits statistical power |
| Li et al., 2015 | General population during 2009 pandemic | 28 | 28 | 135,347 | Seasonal influenza vaccine | Pandemic influenza infection | High | 12 of 28 studies had high risk of bias; significant heterogeneity noted among case-control studies |
| Manzoli et al., 2011 | General population during 2009 pandemic | 33 | 18 | 18,444 | 2009 pandemic vaccine | Influenza seroconversion | Moderate | Most studies included were sponsored by companies developing the vaccine under study |
| Mizumoto et al., 2013 | General population during 2009 pandemic | 17 | 8 | Not reported | Mass antiviral prophylaxis and contact tracing | Secondary infection risk | Moderate | Heterogeneous, arbitrary definitions of "contact", case ascertainment, study setting, and treatment duration |
| Mukerji et al., 2015 | General population during 2009 pandemic | 7 | 3 | Not reported | N-95 masks | Economic benefit | High | Results are of limited utility; limited inclusion of clinical data to inform effectiveness estimates |
| Osterholm et al., 2012 | Canadian and European general population during 2009 pandemic | 5 | 5 | Not reported | 2009 pandemic vaccine | Laboratory-confirmed influenza | Moderate | All studies were observational and of low statistical power |
| Perez Velasco et al., 2012 | General population during 2009 pandemic | 44 | 44 | Not reported | Any | Cost-effectiveness, utility, or benefit | High | Evidence is of low quality and generally inconclusive; variations in intervention implementation |
| Wong et al., 2014 | General population during 2009 pandemic | 10 | 1 | 149 | Hand hygiene and facemask | Laboratory-confirmed influenza or ILI | High | Small sample size of included trial lead to significant imprecision and limited generalizability |
| Yin et al., 2012 | General population during 2009 pandemic | 27 | 27 | 3,011,641 | Seasonal and pandemic influenza vaccines | Laboratory-confirmed influenza | High | Most studies included were of low or moderate quality; significant heterogeneity noted |
| Yin et al., 2011 | General population during 2009 pandemic | 16 | 16 | 17,921 | Pandemic influenza vaccine | Influenza seroconversion | High | Nine of 16 studies were of low quality; significant heterogeneity noted |
* Quality of studies is reported as indicated by the quality assessment of the original authors.